PDL BioPharma Common Stock Net 2010-2020 | PDLI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PDL BioPharma common stock net from 2010 to 2020. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

PDL BioPharma common stock net from 2010 to 2020. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$228.1B
Amgen (AMGN)	$155.2B
Gilead Sciences (GILD)	$148.2B
Vertex Pharmaceuticals (VRTX)	$94B
Bristol Myers Squibb (BMY)	$93.5B
CSL (CSLLY)	$82.7B
GSK (GSK)	$77.1B
Regeneron Pharmaceuticals (REGN)	$59.7B
Alnylam Pharmaceuticals (ALNY)	$57.5B
Argenex SE (ARGX)	$40.5B
BioNTech SE (BNTX)	$26.8B
Insmed (INSM)	$23.2B
Royalty Pharma (RPRX)	$21.1B
Biogen (BIIB)	$19.2B
Incyte (INCY)	$15.3B
Illumina (ILMN)	$14.5B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$13.7B
Ascendis Pharma (ASND)	$11.7B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Moderna (MRNA)	$10.2B
Exelixis (EXEL)	$10.2B
Verona Pharma American Depositary Share (VRNA)	$9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$7.9B
Roivant Sciences (ROIV)	$7.8B
Exact Sciences (EXAS)	$7.8B
Halozyme Therapeutics (HALO)	$7.8B